FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W3097165087> ?p ?o ?g. }

• W3097165087 endingPage "26" @default.
• W3097165087 startingPage "25" @default.
• W3097165087 abstract "Introduction To further improve efficacy and duration of response of CAR-T therapy for Relapsed/Refractory Multiple Myeloma (R/R MM), we have designed a dual FasT CAR-T targeting both B cell maturation antigen (BCMA), a well-established MM target, and CD19, which is expressed on MM cells and their progenitors. Here we report early results from the first-in-human multicenter clinical study (NCT04236011; NCT04182581) to determine safety, pharmacokinetics (PK) and efficacy of BCMA-CD19-directed FasT CAR-T (GC012F) in patients with R/R MM. Methods The BCMA-CD19 dual CAR was constructed by linking BCMA and CD19 scFv, joined by a CD8 hinge, transmembrane domain, co-stimulatory domain and CD3z. Peripheral blood (PB) mononuclear cells were obtained by leukapheresis, T cells were isolated and CAR-T cells were manufactured (FasT CAR platform). From September 2019 to April 2020, we enrolled 16 heavily pretreated R/R MM patients (Age range 27-71), with a median of 5 prior lines of therapies (range 2-7), 93.8% (15/16) of these patients were high risk as defined by mSMART criteria, 5 had extramedullary disease. 4 out of 16 patients had received prior anti CD38 therapy, 93.8% (15/16) patients had received prior IMiD, all patients received at least 1 prior PI and corticosteroids with 3 patients being primary refractory to last therapy. Prior to CAR-T infusion patients received a conditioning regimen over 3 days of 30 mg/m2/d fludarabine and 300 mg/m2/d cyclophosphamide. CAR-T cells were administered in a single infusion at 3 dose levels 1x105/Kg (DL1) (1 patients), 2x105/Kg (DL2) (9 patients) and 3x105/Kg (DL3) (6 patients). Results As of July 17th 2020, all 16 patients were evaluable for response assessment, 15 out of 16 patients responded to treatment (ORR 93.8%) in all dose levels with the earliest response observed at day 28. Best response to date is MRD- CR/sCR in 9/16 patients (56.3%). In DL3 100% (6/6) of patients achieved sCR, 3 at data cut off had been confirmed by PET-CT. In all response evaluable patients, 78.6% (11/14) were MRD- by flow at month 1, and 100% at month 3 (11/11) and 6 (10/10) (sensitivity by flow cytometry measured at 10-4 in 7 patients, and at 10-6 in 9 patients tested by EuroFlow with at least 1.08x107 cells analyzed). At data cut off, the median follow up time was 7.3 months, the longest follow up was 10 months post infusion. CAR-T PK in PB was monitored by qPCR and flow cytometry. The CAR-T median proliferation peak was reached on Day10 (Day8-Day14), and the median peak copy number was 140,982 (16,011-374,346) copies /ug DNA. GC012F showed an acceptable safety profile with 14 out of 16 patients experiencing a cytokine release syndrome (CRS) grade 1-2 (n=14, 87.5%) and 2 grade 3 (n=2, 12.5%). The median duration of CRS was 4 days (1-8 days). No neurotoxicity of any grade was observed. One patient (DL2) presented with fever and died shortly after Day 78 of unknown cause during the COVID-19 Pandemic. Two patients had progression of extramedullary disease while achieving MRD negativity at month 1 and 3, respectively. At landmark analysis at 6 months, all patients in DL3 had achieved and maintained MRD- sCR including patients heavily pretreated including Daratumumab - among them 83.3% (5/6) patients in DL3 had high risk features according to mSMART criteria, and 5 out of 6 patients in DL3 were assessed by 10-6 Euroflow for MRD. The study is still enrolling patients and we will continue to be monitoring safety and efficacy including duration of response. Conclusion The data of BCMA-CD19 dual FasT CAR-T showed an early and high response rate with 93.8% ORR to date with a promising early high MRD-sCR rate in the highest dose level DL3 (100%) which was sustained with a median duration of follow up of 7.3 months at cut off. The data shows very promising activity of the BCMA-CD19 dual FasT CAR-T with a favorable safety profile in R/R MM patients. 93.8% (15/16) of the treated patients exhibited high risk features - a specifically difficult to treat patient population which remains a high unmet medical need in Multiple Myeloma. This data indicates that BCMA-CD19 dual FasT CAR-T (GC012F) may present an effective new treatment option for patients with R/R MM including those with high-risk features who failed multiple prior therapies including anti-CD38. The study is still ongoing and enrolling patients, we will update the results as they become available. Disclosures Zhao: Gracell Biotechnologies Ltd: Current Employment. Han:Gracell Biotechnologies Co., Ltd.: Current Employment. Chen:Gracell Biotechnologies Ltd: Current Employment. Xu:Gracell Biotechnologies Ltd: Current Employment. Zhang:Gracell Biotechnologies Ltd: Current Employment. He:Gracell Biotechnologies Co., Ltd.: Current Employment. Shi:Gracell Biotechnologies Ltd: Current Employment. Han:Gracell Biotechnologies Co., Ltd.: Current Employment. Ye:Gracell Biotechnologies Co., Ltd.: Current Employment. Wang:Gracell Biotechnologies Ltd: Current Employment. Liu:Gracell Biotechnologies Co., Ltd.: Current Employment. Shen:Gracell Biotechnologies Ltd: Current Employment. Cao:Gracell Biotechnologies Ltd: Current Employment. Sersch:Gracell Biotechnologies Co., Ltd.: Current Employment." @default.
• W3097165087 created "2020-11-09" @default.
• W3097165087 creator A5003751560 @default.
• W3097165087 creator A5010689255 @default.
• W3097165087 creator A5015879697 @default.
• W3097165087 creator A5016058980 @default.
• W3097165087 creator A5023640939 @default.
• W3097165087 creator A5024804765 @default.
• W3097165087 creator A5025406557 @default.
• W3097165087 creator A5026572582 @default.
• W3097165087 creator A5039117319 @default.
• W3097165087 creator A5043019475 @default.
• W3097165087 creator A5044036132 @default.
• W3097165087 creator A5047433807 @default.
• W3097165087 creator A5048984565 @default.
• W3097165087 creator A5051650662 @default.
• W3097165087 creator A5055577592 @default.
• W3097165087 creator A5056253982 @default.
• W3097165087 creator A5056450584 @default.
• W3097165087 creator A5056655146 @default.
• W3097165087 creator A5057117256 @default.
• W3097165087 creator A5063481044 @default.
• W3097165087 creator A5069469021 @default.
• W3097165087 creator A5069867873 @default.
• W3097165087 creator A5084145698 @default.
• W3097165087 creator A5089363242 @default.
• W3097165087 creator A5089427194 @default.
• W3097165087 date "2020-11-05" @default.
• W3097165087 modified "2023-09-27" @default.
• W3097165087 title "Clinical Results of a Multicenter Study of the First-in-Human Dual BCMA and CD19 Targeted Novel Platform Fast CAR-T Cell Therapy for Patients with Relapsed/Refractory Multiple Myeloma" @default.
• W3097165087 doi "https://doi.org/10.1182/blood-2020-138614" @default.
• W3097165087 hasPublicationYear "2020" @default.
• W3097165087 type Work @default.
• W3097165087 sameAs 3097165087 @default.
• W3097165087 citedByCount "17" @default.
• W3097165087 countsByYear W30971650872021 @default.
• W3097165087 countsByYear W30971650872022 @default.
• W3097165087 countsByYear W30971650872023 @default.
• W3097165087 crossrefType "journal-article" @default.
• W3097165087 hasAuthorship W3097165087A5003751560 @default.
• W3097165087 hasAuthorship W3097165087A5010689255 @default.
• W3097165087 hasAuthorship W3097165087A5015879697 @default.
• W3097165087 hasAuthorship W3097165087A5016058980 @default.
• W3097165087 hasAuthorship W3097165087A5023640939 @default.
• W3097165087 hasAuthorship W3097165087A5024804765 @default.
• W3097165087 hasAuthorship W3097165087A5025406557 @default.
• W3097165087 hasAuthorship W3097165087A5026572582 @default.
• W3097165087 hasAuthorship W3097165087A5039117319 @default.
• W3097165087 hasAuthorship W3097165087A5043019475 @default.
• W3097165087 hasAuthorship W3097165087A5044036132 @default.
• W3097165087 hasAuthorship W3097165087A5047433807 @default.
• W3097165087 hasAuthorship W3097165087A5048984565 @default.
• W3097165087 hasAuthorship W3097165087A5051650662 @default.
• W3097165087 hasAuthorship W3097165087A5055577592 @default.
• W3097165087 hasAuthorship W3097165087A5056253982 @default.
• W3097165087 hasAuthorship W3097165087A5056450584 @default.
• W3097165087 hasAuthorship W3097165087A5056655146 @default.
• W3097165087 hasAuthorship W3097165087A5057117256 @default.
• W3097165087 hasAuthorship W3097165087A5063481044 @default.
• W3097165087 hasAuthorship W3097165087A5069469021 @default.
• W3097165087 hasAuthorship W3097165087A5069867873 @default.
• W3097165087 hasAuthorship W3097165087A5084145698 @default.
• W3097165087 hasAuthorship W3097165087A5089363242 @default.
• W3097165087 hasAuthorship W3097165087A5089427194 @default.
• W3097165087 hasBestOaLocation W30971650871 @default.
• W3097165087 hasConcept C10205521 @default.
• W3097165087 hasConcept C126322002 @default.
• W3097165087 hasConcept C143998085 @default.
• W3097165087 hasConcept C147483822 @default.
• W3097165087 hasConcept C203014093 @default.
• W3097165087 hasConcept C2776694085 @default.
• W3097165087 hasConcept C2776755627 @default.
• W3097165087 hasConcept C2777371436 @default.
• W3097165087 hasConcept C2778957590 @default.
• W3097165087 hasConcept C2779263901 @default.
• W3097165087 hasConcept C28328180 @default.
• W3097165087 hasConcept C54355233 @default.
• W3097165087 hasConcept C71924100 @default.
• W3097165087 hasConcept C86803240 @default.
• W3097165087 hasConcept C90924648 @default.
• W3097165087 hasConceptScore W3097165087C10205521 @default.
• W3097165087 hasConceptScore W3097165087C126322002 @default.
• W3097165087 hasConceptScore W3097165087C143998085 @default.
• W3097165087 hasConceptScore W3097165087C147483822 @default.
• W3097165087 hasConceptScore W3097165087C203014093 @default.
• W3097165087 hasConceptScore W3097165087C2776694085 @default.
• W3097165087 hasConceptScore W3097165087C2776755627 @default.
• W3097165087 hasConceptScore W3097165087C2777371436 @default.
• W3097165087 hasConceptScore W3097165087C2778957590 @default.
• W3097165087 hasConceptScore W3097165087C2779263901 @default.
• W3097165087 hasConceptScore W3097165087C28328180 @default.
• W3097165087 hasConceptScore W3097165087C54355233 @default.
• W3097165087 hasConceptScore W3097165087C71924100 @default.
• W3097165087 hasConceptScore W3097165087C86803240 @default.
• W3097165087 hasConceptScore W3097165087C90924648 @default.
• W3097165087 hasIssue "Supplement 1" @default.
• W3097165087 hasLocation W30971650871 @default.
• W3097165087 hasOpenAccess W3097165087 @default.

• next